NASDAQ
17.04.26 | 21:59
13,180 US-Dollar
+4,52 % +0,570
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Phathom upgraded at Barclays following pullback, Voquezna optimism | 2 | Seeking Alpha | ||
| 27.03. | Barclays stuft Phathom Pharmaceuticals wegen positiver Umsatzprognose hoch | 3 | Investing.com Deutsch | ||
| 27.03. | Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook | 4 | Investing.com | ||
| 27.02. | Guggenheim raises Phathom stock price target to $25 on revenue beat | 1 | Investing.com | ||
| 26.02. | Phathom outlines $320M-$345M 2026 revenue guidance as company targets operating profitability | 1 | Seeking Alpha | ||
| 26.02. | Stifel reiterates Buy on Phathom stock, keeps $28 price target | 3 | Investing.com | ||
| 26.02. | Phathom Q4 2025 slides: 217% revenue growth, profitability in sight | 3 | Investing.com | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 26.02. | Phathom Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.02. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.01. | Phathom Pharmaceuticals: Stifel bekräftigt "Buy"-Rating nach starkem Umsatzausblick | 7 | Investing.com Deutsch | ||
| 15.01. | Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook | 4 | Investing.com | ||
| 14.01. | Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 | 2 | Investing.com | ||
| 14.01. | Cantor Fitzgerald bestätigt "Overweight" für Phathom und sieht 86 % Kurspotenzial | 6 | Investing.com Deutsch | ||
| 08.01. | Phathom Pharma Shows Sales Strength, Targets 2026 Profitability | 5 | Benzinga.com | ||
| 08.01. | Phathom Pharmaceuticals prices $130 million public offering | 12 | Investing.com | ||
| 08.01. | Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 07.01. | Phathom Pharmaceuticals announces public offering of common stock | 3 | Investing.com | ||
| 07.01. | Phathom Pharma plans public offering after reporting preliminary 2025 results | 1 | Seeking Alpha | ||
| 07.01. | Phathom Pharmaceuticals kündigt nach Kursrallye öffentliches Aktienangebot an | 5 | Investing.com Deutsch | ||
| 07.01. | Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 29,950 | +0,17 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| BIOCRYST PHARMACEUTICALS | 8,100 | +0,40 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2026 Financial Results on May 6 | ||
| IMMUNITYBIO | 6,520 | -0,15 % | ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA Momentum | ||
| MICROBOT MEDICAL | 2,020 | +1,51 % | Microbot Medical stellt auf der Needham Healthcare Conference vor | ||
| ATAIBECKLEY | 3,400 | -0,58 % | Besonders beachtet! Profitiert Emyria vom Analysten-Hype um MDMA-Branchenriesen AtaiBeckley? | ||
| CYTOKINETICS | 56,00 | -1,20 % | Can Myqorzo Drive Growth for Cytokinetics Amid Competition? | ||
| FATE THERAPEUTICS | 1,124 | -5,23 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,482 | -0,29 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,860 | +0,17 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| CAPRICOR | 29,620 | +0,51 % | Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x | ||
| BIOAGE LABS | 15,720 | +0,06 % | BioAge Labs, Inc.: BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 | Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 9,060 | 0,00 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,620 | -1,41 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in New York | CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 17,125 | -1,38 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,705 | +3,63 % | Vir Biotechnology Completes Astellas Deal to Advance Prostate Cancer Immunotherapy |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 13,180 Euro und damit +4,52 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.